Breast Cancer Startup Challenge announces ten winning teams of entrepreneurs; Promising technologies identified to speed cancer researchMarch 5, 2014
Ten winners of a world-wide competition to bring emerging breast cancer research technologies to market faster were announced today by the Avon Foundation for Women, in partnership with NCI and the Center for Advancing Innovation (CAI). Avon is providing $250,000 in funding for this Challenge.
A pilot trial to assess whether assigning treatment based on specific gene mutations can provide benefit to patients with metastatic solid tumors is being launched this month by the NCI. The Molecular Profiling based Assignment of Cancer Therapeutics, or M-PACT, trial is one of the first to use a randomized trial design to assess if assigning treatment based on genetic screening can improve the rate and duration of response in patients with advanced solid tumors.
Introduction of the UroNav was the result of nearly a decade’s research and development, principally conducted at NCI. Resembling a stylized computer workstation on wheels, the system electronically fuses together pictures from magnetic resonance imaging and ultrasound to create a detailed, three-dimensional view of the prostate, which physicians can then use to guide precision biopsies.
To address concerns of colorectal cancer recurring after initial treatment, NCI, in collaboration with SWOG, one of NCI’s cooperative groups, recently announced a phase III trial that looks at whether someone who has been treated for colon cancer in the past can lower his or her risk of having a second primary colorectal cancer or an adenoma by regularly taking one or both of the study drugs, eflornithine and sulindac.
NCI funded a clinical trial that will have an impact on the treatment of late-stage cervical cancer, and also supported a screening trial in India using a network of community outreach workers offering low tech-screening by direct visualization of the cervix coated with dilute acetic acid (vinegar), a process known as VIA. Image depicts cervical cancer microvessel density which increases lethality of the cancer.